Answers are grounded in this paper and cite their sources.
Tens of millions of individuals worldwide, 98% to 99% of whom are male, have used androgens to gain muscle and lose body fat (1). Once largely confined to the elite athletic world, androgen use did not become widespread in the general population until the 1990s. Thus, it is only recently, as sufficient numbers of general-population androgen users have reached middle age, that investigators have become better able to study the long-term effects of these drugs. One such effect is persistent hypogonadism. Androgens suppress the hypothalamic-pituitary-testicular axis via feedback inhibition, and men withdrawing from a course of androgens, often after many months or even years of continuous exposure, may develop profound deficits in testosterone levels and sperm counts. Prior to the year 2000, published descriptions of prolonged androgen-withdrawal hypogonadism, persisting more than a year, were confined to a few case reports or small series (2), and many of us in the field did not anticipate that this issue would become a major public health concern. But now, as more long-term androgen users have entered middle age, it has emerged that we were wrong. In 2013, Coward and colleagues (3) reviewed 6033 cases of men seeking treatment for hypogonadism and found that 97 (1.6%) displayed profoundly depressed testosterone levels of 50 ng/dL (1.73 nmol/L) or less. Forty-two (43%) of these cases were apparently associated with former androgen use (3). In 2015, our group (2) reported that 5 (26%) of 19 former androgen users displayed testosterone levels below 200 ng/dL despite having discontinued androgens 3, 7, 8, 16, and 26 months earlier (2). Seven (37%) of these 19 men scored as having “moderate to severe impairment” on the Sexual Desire Subscale of the International Index of Erectile Function; 5 met diagnostic criteria for major depressive disorder during androgen withdrawal. In 2016, Rasmussen and colleagues (4) evaluated 33 former androgen users who had been abstinent from androgens for a geometric mean (95% CI) of 2.5 (1.7-3.7) years (4). Despite this lengthy abstinence, 9 (27.3%) displayed total testosterone levels below the lower reference limit of 12.1 nmol/L (350 ng/dL), as compared to none of 30 non–androgen-using recreational strength trainers. The former androgen users also exhibited a higher prevalence of depressive symptoms, erectile dysfunction, and decreased libido than nonusers. A 2020 study by Shankara-Narayana and colleagues (5), including 30 former androgen users and 21 nonusers, reported somewhat more optimistic results, finding testicular function “effectively fully reversible” after 6 to 18 months, but testicular volume remained significantly reduced in former users vs nonusers (mean [SEM]: 19 [2] vs 28 [2] mL; P = .004) (5). In 2022, Hashimi (6) described 520 patients reporting past androgen use and sexual symptoms such as erectile dysfunction and low sexual desire (6). These patients were required to remain abstinent from androgen use for the following 12 months and were offered treatment if they failed to improve spontaneously after the first 3 months. Among 463 patients who elected treatment, mean (SD) testosterone levels reached only 14.4 (1.2) nmol/L at the 12-month mark, near the bottom of the reference range of 12 to 32 nmol/L, while the 57 untreated patients achieved a mean of only 9.0 (1.0) nmol/L at 12 months. Vilar Neto and colleagues, in a 2021 review (7), located 168 reported cases of hypogonadism linked exclusively to androgen use. Of the 38 cases for which full outcome data were available, hypogonadism was scored as fully reversible in only 4 (10.5%).
No takes yet. Share an insight, caveat, or question.
Pope et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: